Abstracts tagged "Lupus nephritis"

Abstract Number: 1736 • ACR Convergence 2021
Treatment of Lupus Nephritis with Belimumab Is Associated with Reduction in Urinary CD23
Emma Weeding¹, Andrea Fava², Chandra Mohan³, Daniel Goldman⁴ and Michelle Petri⁴, ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Houston, Houston, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Urine proteomic approaches have shown promise in identifying dynamic biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by…
Abstract Number: 0454 • ACR Convergence 2021
Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities by Race/Ethnicity and Place of Residence and a Recent Worsening Trend
Eric Yen¹, Snehin Rajkumar¹, Rohan Sharma¹ and Ram Singh², ¹University of California Los Angeles, Los Angeles, CA, ²University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Mortality from SLE has improved over the last two decades, but remains disproportionately high relative to general population mortality. Lupus nephritis (LN) occurs in…
Abstract Number: 1280 • ACR Convergence 2021
Generation of Evidence Supporting the Content Validity of SF-36, Lupus-Qol, and FACIT-Fatigue, and Newly Developed Patient-reported Outcome (PRO) Symptom Items to Address Conceptual Gaps for Use in Patient with Lupus Nephritis
Rebecca Hall¹, Nicola Williamson¹, Melissa Barclay¹, Anna Roberts¹, Adam Gater¹, Chloe Tolley¹, Helena Bradley¹, Amy Ward¹, Patricia Delong², Elizabeth Hsia³, Qing Zuraw⁴, Zahi Touma⁵, Vibeke Strand⁶ and Pamela Berry², ¹Adelphi Values Ltd, Bollington, United Kingdom, ²Janssen Global Services, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen R&D, Wayne, PA, ⁵University of Toronto, Mississauga, ON, Canada, ⁶Stanford University School of Medicine, Portola Valley, CA
Background/Purpose: Lupus nephritis (LN) is an autoimmune disease characterized by inflammation of the kidneys, a severe manifestation of systemic lupus erythematosus (SLE) that occurs in…
Abstract Number: 1737 • ACR Convergence 2021
Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial
Emma Weeding¹, Andrea Fava², Chandra Mohan³, Daniel Goldman⁴ and Michelle Petri⁴, ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Houston, Houston, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Urinary CD163 is a macrophage marker which correlates with histological activity index and response to treatment in lupus nephritis (LN), as evidenced by urine…
Abstract Number: 0470 • ACR Convergence 2021
Inhibition of Toll-Like Receptor 7 (TLR7) with the Potent and Selective Inhibitor of Human TLR7 and TLR8 BMS-986256 Provides Robust Efficacy in Murine Lupus Models, Reversing Established Disease
Shailesh Dudhgaonkar¹, Anjuman Rudra¹, Sourabh Ranade¹, Siva Subramani¹, Jignesh Nagar¹, Preethi Karunanithi¹, Priyadeep Bhutani¹, Vishwanath Kurawattimath¹, Rosemary Zhang², Hongchen Qiu², ALARIC DYCKMAN² and Gary Schieven², ¹Biocon Bristol Myers Squibb Research Center, Bangalore, India, ²Bristol Myers Squibb, Lawrenceville, NJ
Background/Purpose: TLR7, a member of the Toll-Like Receptor family, recognizes ssRNA and is primarily expressed in plasmacytoid dendritic cells and B cells. TLR7 has been…
Abstract Number: 1284 • ACR Convergence 2021
One Third of Lupus Nephritis Patients Classified as Complete Responders Continue to Accrue Progressive Renal Damage Despite Resolution of Proteinuria
Emma Weeding¹, Andrea Fava², Daniel Goldman³ and Michelle Petri³, ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Up to 40% of individuals with lupus nephritis (LN) develop chronic kidney disease (CKD). Biopsy studies have revealed that patients with SLE can have…
Abstract Number: 1744 • ACR Convergence 2021
Improvement of Renal and Non-Renal SLE Outcome Measures on Sirolimus Therapy – a 21-year Follow-up Study of 73 Patients
Paramarajan Piranavan¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: The clinical heterogeneity of the SLE makes it often challenging for the treating clinician and also remains one of the many reasons behind failed…
Abstract Number: 0472 • ACR Convergence 2021
An Atlas of Human and Mouse Intrarenal Immune Cells in Lupus Nephritis Reveals Homologous Immune Populations Across Common Mouse Strains and Species
Paul Hoover¹, Michael Peters², David Lieb², Runci Wang³, Garett Dunlap⁴, Deepak Rao¹, Nir Hacohen² and Anne Davidson⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Cambridge, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Harvard University, Somerville, MA, ⁵Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: We discovered 21 immune cell-types in lupus nephritis kidney biopsies as part of the Accelerating Medicines Partnership (AMP) consortium. These immune cells are the…
Abstract Number: 1289 • ACR Convergence 2021
Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms
Philip Carlucci¹, Jessica Li², Heather Gold³, Kristina Deonaraine¹, Andrea Fava², Jill Buyon⁴, Judith James⁵, Chaim Putterman⁶, Deepak Rao⁷, Betty Diamond⁸, Derek Fine², Jose Monroy-Trujillo², Kristin Haag⁹, Accelerating Medicines Partership (AMP) RA/SLE Network¹⁰, H. Michael Belmont⁴, Sean Connery¹¹, Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Parternship In SLE Network¹⁹, Peter Izmirly¹ and Michelle Petri²⁰, ¹New York University School of Medicine, New York, NY, ²Johns Hopkins University, Baltimore, MD, ³NYU Grossman School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Northwell Health, Manhasset, NY, ⁹Johns Hopkins School of Medicine, Baltimore, MD, ¹⁰Brigham and Women's Hospital, Everett, MA, ¹¹Texas Tech University Health Sciences Center, Texas, TX, ¹²Texas Tech University Health Sciences Center, El Paso, TX, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, MI, ¹⁵University of California San Francisco, Corte Madera, CA, ¹⁶University of California San Francisco, San Francisco, CA, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸UC San Diego, La Jolla, CA, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis can occur as an isolated component of disease activity or be accompanied by diverse extrarenal symptoms that can adversely affect a patient’s…
Abstract Number: 1745 • ACR Convergence 2021
Pre-pregnancy Switching from Mycophenolate to Azathioprine in Patients with Lupus Nephritis: A Retrospective Outcome Analysis
Saadia Ali¹, Shirish Sangle², Maha Al Falah³ and David D'Cruz⁴, ¹Guys and St Thomas' Hospital NHS Trust, Epsom, United Kingdom, ²Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom, ³Guys and St Thomas' Hospital NHS Trust, Saudi Arabia, United Arab Emirates, ⁴Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Background/Purpose: Mycophenolate Mofetil is not recommended in pregnancy due to teratogenic effects. A previous small prospective study found that switching from MMF to AZA rarely…
Abstract Number: 0274 • ACR Convergence 2020
The Rising Incidence of Lupus Nephritis: A Population-Based Study of Four Decades
Mehmet Hocaoglu¹, Shirley-Ann Osei-Onomah², Jesse Dabit³, Rachel Giblon³, Thomas O'Byrne³, Fernando C. Fervenza³, Cynthia Crowson⁴ and Ali Duarte-Garcia³, ¹University of Maryland Medical Center Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Estimating the incidence of lupus nephritis (LN) is important to understand disease burden, particularly since patients with LN have a higher morbidity and mortality…
Abstract Number: 0976 • ACR Convergence 2020
Kidney-infiltrating T Cells in Murine Lupus Nephritis Exhibit Transcriptional Heterogeneity and Oligoclonal Expansion
Shuchi Smita¹, Minjung Kim¹, Maria Chikina¹, Mark Shlomchik¹ and Jeremy Tilstra¹, ¹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Lupus nephritis (LN) is a hallmark of SLE, affecting 50-60% of patients within 10 years of diagnosis. Current treatments for LN have suboptimal response…
Abstract Number: 1674 • ACR Convergence 2020
Pediatric and Adolescent One Year Protocol Kidney Biopsies Should Be Performed, Even in Patients with Complete Remission of Their Lupus Nephritis
Peter Yorgin¹, Suhas Radhakrishna¹, Caitlin Carter¹, Johanna Chang¹, Katayoon Shayan¹, Lieuko Nguyen¹, Peter Chiraseveenuprapund¹ and Robert Sheets², ¹UCSD/Rady Children's Hospital, San Diego, CA, ²University of California San Diego, San Diego, CA
Background/Purpose: The value of one-year protocol kidney biopsies in children who have proliferative lupus nephritis (LN) is unclear, particularly in patients who meet CARRA criteria…
Abstract Number: 1836 • ACR Convergence 2020
Alternative Renal Response Definitions in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis
Zahir Amoura¹, Philippe Remy², Luis Fernando Quintana Porras³, Laurent Chiche⁴, Dominique Chauveau⁵, Dario Roccatello⁶, Richard Furie⁷, Thomas Schindler⁸, Jay Garg⁹, Matthew Cascino⁹, Brad Rovin¹⁰ and Andrea Doria¹¹, ¹Hôpital Pitié-Salpêtrière, Paris, ²APHP Groupe Hospitalier Henri-Mondor, Creteil, France, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁴Hôpital Européen, Marseille, France, ⁵Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France, ⁶S Giovanni Hospital, Univ of Turin, Turin, Italy, ⁷Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁸F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁹Genentech, Inc., South San Francisco, CA, ¹⁰The Ohio State University, Columbus, ¹¹University of Padua, Padua, Italy
Background/Purpose: Obinutuzumab, a type II anti-CD20 mAb, resulted in rapid and complete B-cell depletion and improved renal responses in proliferative lupus nephritis (LN) in the…
Abstract Number: 0288 • ACR Convergence 2020
Targeted Sequencing Revealed Novel Candidate Genetic Contributions to Lupus Nephritis in a Cohort of Swedish Patients with Systemic Lupus Erythematosus
Sule Yavuz¹, Pascal Pucholt², Dag Leonard², Juliana Imgenberg-Kreuz², Matteo Bianchi², Johanna Sandling², Iva Gunnarsson³, Swedish Sle Network² and Lars Ronnblom², ¹Uppsala University Rheumatology, Doral, FL, ²Uppsala University, Uppsala, Sweden, ³Karolinska Institute, Stockholm, Sweden
Background/Purpose: Lupus nephritis (LN) is a common debilitating manifestation of Systemic Lupus Erythematosus (SLE). Despite improved understanding of underlying mechanisms driving to LN and early…